Virtual Library

Start Your Search

E. Cathcart-Rake



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      20P - ArgSS1 expression in squamous cell carcinoma of the lung (ID 294)

      12:30 - 13:00  |  Presenting Author(s): E. Cathcart-Rake

      • Abstract
      • Slides

      Background:
      Diminished or absent expression of the enzyme argininosuccinate synthetase 1 (ArgSS1 or ASS1) portends chemotherapy resistance and poor prognosis in a number of tumor types, suggesting arginine depletion is a viable therapeutic strategy in ArgSS1 deficient tumors. ArgSS1 expression and its implications on prognosis have not been studied in squamous cell carcinoma of the lung.

      Methods:
      Resected pathology specimens were collected from patients with squamous cell carcinoma of the lung and analyzed for ArgSS1 expression by IHC. ArgSS1 expression was deemed intact if there was >50% expression in tumor cells and deficient if there was ≤50%. Chart reviews were conducted to abstract patient demographic and oncologic information. Pearson's correlations were utilized to evaluate potential associations between ArgSS1 status and oncologic variables. The Kaplan-Meier estimator was used to evaluate a potential association between ArgSS1 expression and survival which was compared with a log-rank test.

      Results:
      Sixty-seven specimens of squamous cell carcinoma of the lung were evaluated. Patients were diagnosed at a mean age of 66.9 years (SD 9.1). The majority of patients were male (64.2%). 97% were current or former smokers, and 89.6% had early stage disease. Most patients (64.2%) had moderately differentiated tumors. Nineteen (28.3%) tumors were ArgSS1 deficient. We did not find any significant associations between ArgSS1 expression and gender, tobacco use, stage at diagnosis, or tumor differentiation. There was no significant difference in overall survival between those who had intact ArgSS1 expression (median 42 months, interquartile range 28-not reached) and those who did not (median not reached, interquartile range 14-not reached; HR = 0.19; p = 0.66).

      Conclusions:
      Despite the associations of ArgSS1 deficiency and poor survival in other malignancies, we did not observe an association between ArgSS1 and overall survival in patients with squamous cell carcinoma of the lung. Our findings might be limited by our sample size. Even if ArgSS1 is not a prognostic marker in squamous cell carcinoma of the lung, it may still have predictive significance given the development of arginine deaminases in clinical trials. Preclinical work is ongoing with cell lines to study this further.

      Clinical trial identification:


      Legal entity responsible for the study:
      Mayo Clinic

      Funding:
      Has not received any funding

      Disclosure:
      A. Mansfield: Payments to his institution from AbbVie, Genentech, BMS and Trovagene for consulting, and payment to his institution from Novartis for research. All other authors have declared no conflicts of interest.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.